Seminari di Ematologia Oncologica - Società Italiana di Ematologia

cell lymphomas: initial features, natural history and
prognostic factors in a series of 174 patients
diagnosed to the REAL Classification. Ann Oncol.
1998, 9: 849-55.
17. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma:
clinico-pathological findings and outcome. Blood
1999; 93. 2697-706.
18. Suzumiya J, Ohshima K, Tamura K, et al. The
International Prognostic Index predicts outcome in
aggressive adult T-cell leukaemia/lymphoma: analysis
of 126 patients from the International Peripheral T Cell
Lymphoma Project. Ann Oncol. 2009; 20: 715-20.
19. Au WY, Weisenburger DD, Intragumtornchai T, et al.
Clinical difference between nasal and extranasal
natural killer/T cell lymphoma: a study of 136 cases
from the International T Cell Lymphoma Project. Blood.
2009; 113: 3931-7.
20. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T cell
lymphoma, unspecified (PTCL-U): a new prognostic
model from a retrospective multicentric clinical study.
Blood. 2004; 103: 2474-9.
21. Briones J, Moga E, Espinosa I, et al. Bcl-10 protein
highly correlates with the expression of phosphorylated
p65 NK-kappaB in peripheral T cell lymphomas and
os associated with clinical outcome. Histopatology.
2009; 54: 478-85.
22. Lee J, Suh C, Park YH, et al. Extranodal natural killer
T cell lymphoma, nasal type: a prognostic model from
a retrospective multicenter study. J Clin Oncol. 2006;
24: 612-8.
23. Suzuki R, Suzimiya J, Yamagughi M, et al. Prognostic
factors for mature killer (NK) cell neoplasms: aggressive
NK cell leukaemia and extranodal NK cell lymphoma,
nasal type. Ann Oncol. 2010; 21: 1032-40.
24. Kluin PM, Feller A, Gaulard P, et al. Peripheral T/NK
cell lymphoma: a report og IXth Workshop of the
European Association for Haematopathology.
Histopathology. 2001; 38: 250-70.
25. Dupuis J, Emile JF, Mounier N, et al. Prognostic
significance of Epstein Barr virus in nodal peripheral
T cell Lymphoma, unspecified : A Group d’Etude des
Lymphomes de d’Adulte (GELA) study. Blood. 2006;
108: 4136-69.
26. Au WY, Pang A, Choy C, et al. Quantification of
circulating Epstein Barr virus (EBV) DNA in the
diagnosis and monitoring of natural killer cell and EBVpositive
lymphomas in immunocompetent patients.
Blood. 2004; 104: 243-9.
27. Lee J, Suh C, Huh J, et al. Effect of positive bone
marrow EBV in situ hybridization in staging and survival
of localized extranodal natural killer/T cell lymphoma,
nasal type. Clin Cancer Res. 2007; 13: 3250-4.
28. Martinez-Delgado B, Cuadros M, Honrado E, et al.
Differential expression of NF-kappaB pathway genes
among peripheral T cell lymphomas. Leukemia. 2005;
19: 2254-63.
29. O’Leary H, Savage K. The spectrum of peripheral T cell
Linfomi non Hodgkin T/NK
lymphomas. Curr Opin Hematol. 2009; 16: 292-8.
30. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T
cell lymphomas: initial features, natural history, and
prognostic factors in a series of 174 patients diagnosed
according to the REAL Classification. Ann Oncol. 1998;
9: 849-55.
31. Gisselbrecht C, Gaulrd P, Lepage E, et al. Prognostic
significance of T cell phenotype in aggressive non
Hodgkin’s lymphomas. Groupe d’Etudes des
Lymphomes de l’Adulte (GELA). Blood. 1998; 92:
76-82.
32. Chang ST, Lu CL, Chuang SS. CD52 expression in nonmycotic
T and NK/T cell lymphomas. Leuk Lymphoma.
2007; 48: 117-21.
33. Piccaluga PP, Ascani S, Agostinelli C, et al. Expression
of CD52 in peropheral T cell lymphoma.
Haematologica. 2007; 92: 566-7.
34. Rodig SJ, Abramson JS, Pinkus GS, et al.
Heterogeneous CD52 expression among hematologic
neoplasms: implications for the use of Alemtuzumab
(CAMPATH-1H). Clin Cancer Res. 2006; 12: 7174-9.
35. Rizvi MA, Evens AM, Tallman MS, et al. T cell non
Hodgkin’s lymphoma. Blood. 2006; 107: 1255-64.
36. Zettl A, Rudiger T, Konrad MA, et al. Genomic
profiling of peripheral T cell lymphoma, unspecified, and
anaplastic large T cell lymphoma delineates novel
recurrent chromosomal alterations. Am J Pathol.
2004; 164: 1837-48.
37. Basem M. William, Maribeth Hohenstein, Fausto R, et
al. Phase I/II study of dasatinib in relapsed or refractory
non-Hodgkin’s lymphoma (NHL). Blood. 2010; 116 (21):
Abs 288.
38. Martinez-Delgado B, Mendelez B, Cuadros M, et al.
Expression profiling of T-cell lymphomas differentiates
peripheral and lymphoblastic lymphomas and defines
survival related genes. Clin Cancer Res. 2004; 10:
4971-82.
39. Ballestrer B, Ramuz O, Gisselbrecht C, et al. Gene
expression profiling identifies molecular subgroups
among nodal peripheral T cell lymphomas. Oncogene
2006; 25: 1560-71.
40. Beltran B, Morales D, Quinones P, et al. Lymphopenia
predicts survival in peripheral T cell lymphoma,
unspecified. [Abstract]. Blood. 2009; 114 (22): 1930.
41. Choi DR, Yoon DH, Ahn JH, et al. Significance of
absolute lymphocyte count at relapse as a prognostic
factor in patients with t cell non Hodgkin’s lymphoma.
[Abstract]. Blood 2009; 114 (22): 2939.
42. Salaverria I, Bea S, Lopez-Guillermo, A et al.
Genomic profiling reveals different genetic aberrations
in systemic ALK-positive and ALK-negative anplastic
large cell lymphomas. Br J Haematol. 2008; 140:
516-26.
43. Gascoyne RD, Aoun P, Wu D, et al. Prognostic
significance of anaplastic lymphoma kinase (ALK)
protein expression in adults with anaplastic large cell
lymphoma. Blood. 1999; 93: 3913-21.
77